AstraZeneca (CHIX:AZNL) Cyclically Adjusted Revenue per Share: £23.70 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AZNL AstraZeneca PLC CHIX:AZNL
88 GF Score
Price £117.58
GF Value £133.33
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted Revenue per Share?

AstraZeneca CHIX:AZNL +2.64% 88 Cyclically Adjusted Revenue per Share is £23.70 as of Jun. 2026. GuruFocus rates CHIX:AZNL with a GF Score™ of 88/100 and a GF Value™ of £133.33 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share for the three months ended in Jun. 2026 was £7.396. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is £23.70 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca was 9.90% per year. The lowest was -0.20% per year. And the median was 5.30% per year.

As of today (2026-08-05), AstraZeneca's current stock price is £117.58. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was £23.70. AstraZeneca's Cyclically Adjusted PS Ratio of today is 4.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


AstraZeneca  (CHIX:AZNl) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=117.58/23.70
=4.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Cyclically Adjusted Revenue per Share Related Terms


AstraZeneca Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted Revenue per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.71 17.83 19.16 20.83 22.60

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.90 22.26 22.60 23.15 23.70

CHIX:AZNL vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


CHIX:AZNL
88GF Score
AstraZeneca PLC CHIX:AZNL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.396/142.3000*142.3000
=7.396

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.426 101.500 4.803
201612 3.534 102.200 4.921
201703 3.458 102.700 4.791
201706 3.116 103.500 4.284
201709 3.689 104.300 5.033
201712 3.393 105.000 4.598
201803 2.926 105.100 3.962
201806 3.060 105.900 4.112
201809 3.224 106.600 4.304
201812 4.001 107.100 5.316
201903 3.287 107.000 4.371
201906 3.502 107.900 4.618
201909 3.945 108.400 5.179
201912 3.873 108.500 5.080
202003 3.910 108.600 5.123
202006 3.819 108.800 4.995
202009 3.871 109.200 5.044
202012 4.199 109.400 5.462
202103 4.001 109.700 5.190
202106 4.447 111.400 5.681
202109 4.801 112.400 6.078
202112 5.783 114.700 7.175
202203 5.538 116.500 6.764
202206 5.606 120.500 6.620
202209 6.220 122.300 7.237
202212 5.898 125.300 6.698
202303 5.746 126.800 6.448
202306 5.796 129.400 6.374
202309 5.952 130.100 6.510
202312 6.085 130.500 6.635
202403 6.396 131.600 6.916
202406 6.519 133.000 6.975
202409 6.565 133.500 6.998
202412 7.541 135.100 7.943
202503 6.737 136.100 7.044
202506 6.834 138.400 7.027
202509 7.201 138.900 7.377
202512 7.409 139.900 7.536
202603 7.345 140.800 7.423
202606 7.396 142.300 7.396

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of £23.70 mean?
AstraZeneca (CHIX:AZNL) has a Cyclically Adjusted Revenue per Share of £23.70 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted Revenue per Share too high?
AstraZeneca's current Cyclically Adjusted Revenue per Share is £23.70. Overall, AstraZeneca has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted Revenue per Share of £23.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted Revenue per Share is £23.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (CHIX:AZNL) is currently considered Modestly Undervalued. The stock's GF Value™ is £133.33, compared to a current price of £117.58 — trading 11.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is £23.70. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AstraZeneca (CHIX:AZNL), the current Cyclically Adjusted Revenue per Share is £23.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (CHIX:AZNL) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of £117.58 is trading 11.8% below its estimated GF Value™ of £133.33. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for CHIX:AZNL:

  • Cyclically Adjusted Revenue per Share: £23.70
  • GF Value™: £133.33 vs. price of £117.58 (11.8% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the CHIX:AZNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for CHIX:AZNL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£117.58
Price
£133.33
GF Value